Sensitization of ovarian carcinoma cells to Bcl-xL-targeting strategies through indirect modulation of Mcl-1 activity by MR22388, a molecule of the tripentone family

Journal of Ovarian Research

Laurent Poulain¹  Pascal Gauduchon²  Sylvain Rault³  Edwige Abeilard¹  Marie-Hélène Louis¹  Emilie Brotin¹  Florence Giffard¹  Aurélie Malzert-Freon³  Julie Tomasina³ 

[1] Centre de Lutte Contre le Cancer F. Baclesse, F-14032, Caen, France;UNICAEN, BioTICLA EA 4656, F 14032, Caen, France;UNICAEN, CERMN EA 4258, F-14032, Caen, France

关键词: Chemoresistance;    Apoptosis;    Ovarian cancer;    Tripentone MR22388;   

Others  :  810515
DOI  :  10.1186/1757-2215-6-38

 received in 2013-03-22, accepted in 2013-05-25,  发布年份 2013

【 摘 要 】

Background

Our work has been carried out in the context of the therapeutic failure in ovarian carcinoma, which remains the leading cause of death by gynecologic malignancy. In these tumours, recurrence and subsequent acquired chemoresistance constitute major hurdles to successful therapy. Here we studied the interest of a member of the tripentone chemical family, MR22388, for the treatment of chemoresistant ovarian cancer cells.

Findings

MR22388 activity has been assessed in vitro on cisplatin-resistant (SKOV3 and IGROV1-R10) ovarian cancer cell lines by conventional analysis, alone or combined to a BH3-mimetic molecule, ABT-737. MR22388 exerts its activity on cisplatin resistant cells, and we showed that it induces a decrease of the Mcl-1 anti-apoptotic protein expression. Considering our previous work demonstrating that the efficiency of Bcl-x_L targeting strategies is conditioned to the concomitant inhibition of Mcl-1 we studied the interest of the association of this MR22388 with ABT-737, and showed that this combination was highly cytotoxic in chemoresistant cells.

Conclusions

This work thus opens new perspectives for the use of this promising molecule for the treatment of highly chemoresistant ovarian cancer cells and for sensitization of emerging Bcl-x_L targeting strategies such as the use of BH3-mimetic molecules.

【 授权许可】

   
2013 Tomasina et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012, 62(1):10-29.
• [2]Ozols RF: Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit. J Clin Oncol 2003, 21:2451-2453.
• [3]Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
• [4]Rabik CA, Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007, 33:9-23.
• [5]Villedieu M, Louis MH, Dutoit S, Brotin E, Lincet H, Duigou F, Staedel C, Gauduchon P, Poulain L: Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells. Gynecol Oncol 2007, 105:31-44.
• [6]Simonin K, Brotin E, Dufort S, Dutoit S, Goux D, N’diaye M, Denoyelle C, Gauduchon P, Poulain L: Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells. Mol Cancer Ther 2009, 8(11):3162-3170.
• [7]Brotin E, Meryet-Figuière M, Simonin K, Duval RE, Villedieu M, Leroy-Dudal J, Saison-Behmoaras E, Gauduchon P, Denoyelle C, Poulain L: Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis. Int J Cancer 2010, 126:885-895.
• [8]Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM, Huang DC: Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005, 19(11):1294-1305.
• [9]Rochais C, Dallemagne P, Rault S: Tripentones: a promising series of potent anti-cancer agents. Anti Cancer Agents Med Chem 2009, 9:369-380.
• [10]Rochais C, Cresteil T, Perri V, Jouanne M, Lesnard A, Rault S, Dallemagne P: MR22388, a novel anti-cancer agent with a strong FLT-3 ITD kinase affinity. Cancer Lett 2013, 331(1):92-98.
• [11]Rochais C, Lescot E, Lisowski V, Lepailleur A, Santos JS, Bureau R, Dallemagne P, Meijer L, Rault S: Synthesis and biological evaluation of thienopyrrolizines, a new family of CDK/GSK-3 inhibitors. J Enzyme Inhib Med Chem 2004, 19:585-593.
• [12]Poulain L, Lincet H, Duigou F, Deslandes E, Sichel F, Gauduchon P, Staedel C: Acquisition of chemoresistance in a human ovarian carcinoma cell is linked to a defect in cell cycle control. Int J Cancer 1998, 78:454-463.
• [13]Simonin K, N’diaye M, Lheureux S, Loussouarn C, Dutoit S, Briand M, Giffard F, Brotin E, Blanc-Fournier C, Poulain L: Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis. Apoptosis 2013. Epub ahead of print
• [14]Ke N, Wang X, Xu X, Abassi YA: The xCELLigence system for real-time and label-free monitoring of cell viability. Methods Mol Biol 2011, 740:33-43.
• [15]Lisowski V, Enguehard C, Lancelot J, Caignard D, Lambel S, Leonce S, Pierre A, Atassi G, Renard P, Rault S: Design, synthesis and antiproliferative activity of tripentones: a new series of antitubulin agents. Bioorg Med Chem Lett 2001, 11:2205-2208.
• [16]Lisowski V, Léonce S, Kraus-Berthier L, Sopková-de Oliveira Santos J, Pierré A, Atassi G, Caignard DH, Renard P, Rault S: Design, synthesis, and evaluation of novel thienopyrrolizinones as antitubulin agents. J Med Chem 2004, 47:1448-1464.
• [17]Thomas LW, Abburi C, Edwards SW: Mcl-1; the molecular regulation of protein function. FEBS Lett 2010, 584(14):2981-2989.
• [18]Inoshita S, Takeda K, Hatai T, Terada Y, Sano M, Hata J, Umezawa A, Ichijo H: Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress. J Biol Chem 2002, 277:43730-43734.
• [19]Michels J, Johnson PW, Packham G: Mcl-1. Int J Biochem Cell Biol 2005, 37:267-271.
• [20]Basu A, Haldar S: Identification of a novel Bcl-xL phosphorylation site regulating the sensitivity of taxol- or 2-methoxyestradiol-induced apoptosis. FEBS Lett 2003, 538(1–3):41-47.
• [21]El Fajoui Z, Toscano F, Jacquemin G, Abello J, Scoazec JY, Micheau O, Saurin JC: Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL. Gastroenterology 2011, 141(2):663-673.
• [22]Upreti M, Galitovskaya EN, Chu R, Tackett AJ, Terrano DT, Granell S, Chambers TC: Identification of the major phosphorylation site in Bcl-xL induced by microtubule inhibitors and analysis of its functional significance. J Biol Chem 2008, 283(51):35517-35525.
• [23]Wang J, Beauchemin M, Bertrand R: Phospho-Bcl-x(L)(Ser62) plays a key role at DNA damage-induced G(2) checkpoint. Cell Cycle 2012, 11(11):2159-2169.
• [24]Morel C, Carlson SM, White FM, Davis RJ: Mcl-1 integrates the opposing actions of signaling pathways that mediate survival and apoptosis. Mol Cell Biol 2009, 29:3845-3852.
• [25]Wei G, Margolin AA, Haery L, Brown E, Cucolo L, Julian B, Shehata S, Kung AL, Beroukhim R, Golub TR: Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell 2012, 21(4):547-562.